Remission of progressive multifocal leukoencephalopathy following highly active antiretroviral therapy in a man with AIDS

Katie Yoganathan1
David Brown2
Kathir Yoganathan3

1Cardiff Medical School, Cardiff, Wales, UK; 2Virus Reference Department, Microbiology Services, Health Protection Agency, London, UK; 3Singleton Hospital, Abertawe Bro Morgannwg University Health Board, Swansea, UK

Correspondence: Kathir Yoganathan GU/HIV Medicine, Singleton Hospital, Abertawe Bro Morgannwg University Health Board, Swansea SA2 8QA, UK Email kathir.yoganathan@wales.nhs.uk

Abstract: A 43-year-old Caucasian homosexual man with AIDS presented with blurring of vision, change of personality, and memory loss in March 1999. He had first been admitted 2 months previously for treatment of Pneumocystis jiroveci pneumonia. A magnetic resonance imaging scan on admission showed multiple white matter lesions involving both subcortical cerebral hemispheres and cerebellar regions, with no mass effect or surrounding edema. JC virus was detected by nested polymerase chain reaction in the cerebrospinal fluid. These findings were diagnostic of progressive multifocal leukoencephalopathy (PML). His CD4 count was 34 cells/mL, and his HIV ribonucleic acid level was 800,789 copies/mL. He was treated with a combination antiretroviral therapy. He was last reviewed in October 2011. He was fully independent socially and mentally, but he still had some residual neurologic signs with right-sided homonymous hemianopia and visual agnosia. His HIV ribonucleic acid level was undetectable, and his CD4 count was 574 cells/mm³. Although the median survival of patients with PML was poor before the antiretroviral therapy era, our patient, who is now aged 55 years, is still alive 12 years after the diagnosis. The diagnosis of PML and differential diagnosis of focal neurologic signs in HIV-positive patients are discussed in this case report.

Keywords: HIV, focal neurologic signs, cerebral toxoplasmosis, primary brain lymphoma, ischaemic stroke

Case report

A 43-year-old Caucasian man with AIDS presented with progressive confusion, blurring of vision, and personality change for 6 weeks in March 1999. He was successfully treated for Pneumocystis jiroveci pneumonia 2 months prior to his presentation. He did not have any headaches or seizures. He was afebrile. Examination revealed left cerebellar signs, dysphasia, and clear evidence of left posterior-occipital lesion with right homonymous hemianopia. He was unable to identify simple objects such as a pen or coins nor name colors correctly. He was disoriented in time and place. His CD4 count was 34 cells/mm³. His HIV ribonucleic acid (RNA) level was 800,789 copies/mL. Serum toxoplasma immunoglobulin G antibodies were negative. A magnetic resonance imaging (MRI) scan on admission showed multiple white matter lesions involving both subcortical cerebral hemispheres and cerebellar regions, with no mass effect or surrounding edema (Figure 1). Cerebrospinal fluid (CSF) was clear in color with a polymorph count of three cells and a lymphocyte count of five cells. Gram staining of CSF did not show any organism, and bacterial culture of CSF was negative. CSF toxoplasma PCR was negative. CSF Mycobacterium tuberculosis culture was negative. JC virus antibodies in the blood and CSF were 1/81,920 and 1/20,489, respectively. The antibody index was 28, indicating intrathecal production of JC virus antibodies, which was consistent
with progressive multifocal leukoencephalopathy (PML). Nested PCR for JC virus was positive in the CSF.

He was treated with nucleoside reverse transcriptase inhibitors, zidovudine (AZT), lamivudine, and the non-nucleoside reverse transcriptase inhibitor nevirapine. His cerebellar signs improved 2 months after the treatment. He was oriented in time and place. He was able to walk independently to the local shops and to pay money correctly a year after admission. He became fully independent and able to live on his own nearly 2 years after his admission, though he required frequent visits by a support worker to supervise adherence to his antiretroviral therapy (ART). His HIV RNA level became undetectable, and his CD4 count rose to 330 cells/mm³. He developed symptoms of peripheral neuropathy 9 months after commencing ART. Zidovudine was replaced with abacavir. He was last reviewed in October 2011 when he was 55 years old. His adherence to ART was excellent without requiring any support from health care workers. He was fully independent and living on his own but still had some residual neurologic signs with homonymous hemianopia. He declined repeat lumbar puncture to look for JC virus in the CSF, as he felt that there was no reason to undergo invasive tests whilst he remained well. He is now reviewed in our HIV follow-up clinic every 6 months. His most recent HIV RNA level was undetectable, and his CD4 count was 574 cells/mm³.

Discussion

PML is an opportunistic infection caused by a human polyomavirus, JC virus. The initial site of JC virus infection is thought to be the tonsils, and it is then carried via lymphocytes to the kidney and bone marrow, which are the sites of viral latency. Reactivation of JC virus occurs due to immunosuppression, and the virus crosses the blood–brain barrier within B lymphocytes and infects oligodendrocytes and astrocytes, causing widespread demyelinating lesions.²

PML is an AIDS-defining illness in approximately 1%–3% of HIV-positive patients. It occurs almost exclusively in severely immunocompromised HIV-positive patients with CD4 counts less than 100 cells/mm³, as in our case.¹ It was invariably fatal in patients with AIDS before the advent of ART, with median survival around 6 months. Our patient is still alive 12 years after the diagnosis of AIDS-related PML. Astrom et al⁴ first described PML in patients with chronic lymphocytic leukemia and Hodgkin's lymphoma in 1958. Although the prevalence of PML increased significantly during the HIV epidemic, it has also been widely reported in other non-HIV conditions, such as systemic lupus erythematosus and sarcoidosis, and in patients with organ transplants.⁵ More recently, PML has also been associated with HIV-negative patients treated with immunomodulatory drugs, especially natalizumab.⁶,⁷ The risk of developing PML is 1.47 in 1000 in patients with multiple sclerosis who are treated with natalizumab, which is similar to the risk of developing PML (one in 1000) in patients with systemic lupus erythematosus who are treated with rituximab.⁸

PML has also been reported in HIV-negative patients who are treated with other monoclonal antibodies such as efalizumab in patients with psoriasis. PML has also been recognized in HIV-negative patients with the use of immunosuppressive agents such as azathioprine, cyclophosphamide, methotrexate, mycophenolate, and fludarabine. Fludarabine is the most frequently implicated among immunosuppressive drugs with PML, as it is capable of depleting T lymphocytes.⁹

New onset of PML has been observed after initiation of ART. A rapid recovery of the immune system can trigger immune reconstitution inflammatory syndrome (PML-IRIS), which is an inflammatory reaction to clinically apparent or subclinical pathogens of JC virus.¹⁰ PML-IRIS has been reported in up to 23% of PML cases diagnosed in HIV-positive patients.¹¹ This inflammatory reaction is often associated with contrast enhancement with edema and possible mass effect on an MRI scan. It is often acute in onset, and JC virus PCR in the CSF can be negative.¹²

PML patients present with a slow onset of focal neurologic features without any headaches, fever, or altered consciousness. Hemiparesis, hemianopia, aphasia, hemisensory defects, and ataxia are common features. Headaches, seizures, and neck stiffness are rare in patients with PML.¹³ Other common causes of focal neurologic features in HIV-positive patients
include cerebral toxoplasmosis and primary brain lymphoma. They often present with symptoms of raised intracranial pressure such as headaches or seizures and rapidly progressive focal neurologic features. Radiologic imaging often shows multiple cerebral abscesses with surrounding edema in patients with cerebral toxoplasmosis and mass effect with cerebral edema in patients with primary brain lymphoma. Ischemic strokes in young AIDS patients causing focal neurologic signs due to acquired deficiency of protein S and C have also been reported.\(^\text{14}\)

For diagnosing PML, MRI is superior to computed tomography and shows multiple white matter lesions without any mass effect or surrounding edema, and lesions are not contrast enhancing. The occipito-parietal and frontal areas are most commonly affected. Lesions in thalamus, basal ganglia, corpus callosum, and posterior fossa are rare. In our patient, lesions were found in occipito-parietal areas, causing homonymous hemianopia and visual agnosia, and in the cerebellum, causing cerebellar dysfunction.\(^\text{15}\) CSF is usually normal in terms of protein, glucose, and cell counts, which help to rule out other etiologies such as cryptococcal meningitis, tuberculous meningitis, or cerebral toxoplasmosis. JC virus PCR of the CSF has been shown to have specificity (92%–99%) and sensitivity (75%).\(^\text{16}\) However, CSF PCR for JC virus PCR of the CSF has been shown to have specificity (92%–99%) and sensitivity (75%).\(^\text{16}\) However, CSF PCR for JC virus can be negative in 25% of patients, especially in those with deep-seated lesions. Because JC virus is intermittently shed in the CSF, repeated CSF analysis may increase the sensitivity. A negative PCR, therefore, will not exclude PML. Quantifying JC virus DNA level is a useful tool to monitor the disease progression of PML.\(^\text{17}\) This was not done in our patient, as it was not available at our hospital in 1999. JC virus antibodies in the CSF, in comparison with the blood in our patient, indicate that these antibodies are produced in the CSF and are not crossed from the blood. This was confirmed by a high antibody index.\(^\text{18,19}\) Definitive diagnosis is made by brain biopsy, which characteristically shows a triad of demyelination, enlarged nuclei with inclusions of oligodendrocytes, and giant bizarre astrocytes.\(^\text{20}\)

There is no effective therapy for PML. However, cytosine arabinoside, cidofovir, and meflaquine have been tried with various success.\(^\text{21–24}\) The prognosis has been improved with the use of ART, which suppresses HIV RNA level and improves immune function by raising CD4 counts. Regulatory protein Tat, which is found in HIV, is known to upregulate JC virus replication.\(^\text{25}\) The use of ART with a high central nervous system penetration effective score might be associated with prolonged survival of patients with HIV-related PML. Zidovudine and nevirapine are usually selected in the combination ART regimen in treating HIV-positive patients with PML. These agents halt the progression of demyelination by downregulating JC virus replication and improving survival, as in our patient.

Our patient, who was severely immunocompromised due to HIV infection, had clinical, virologic, and radiologic evidence of PML. Moreover, he did not have any other causes for his focal neurologic signs. The fact that the majority of his neurologic deficits improved with the rise of CD4 count due to the use of ART strongly suggests that his PML is in remission clinically following immune reconstitution 12 years after the diagnosis of AIDS-related PML.

In conclusion, slowly progressive focal neurologic features without any headaches or seizures, and multiple subcortical white matter lesions without any mass effect or surrounding edema with positive JC virus DNA in the CSF in an AIDS patient, are diagnostic of PML. In addition, it is not invariably fatal after the introduction of ART.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


25. Gasnault J, Lanoy E, Bentata M, Galgust M, Costagliola D. Intracerebral penetrating ART are more efficient on survival of HIV+ patients with progressive multifocal leucoencephalopathy (ANRS CO4-FHDH). Poster presented at the 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009, Montreal, QC, Canada.